HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ELISA inhibition test using monoclonal antibody specific for Treponema pallidum as the serologic test for syphilis.

Abstract
Monoclonal antibodies (Mabs) specific for Treponema pallidum were produced using hybridoma technology. In this study an ELISA inhibition test based on competitive inhibition by antibodies from human test sera of the binding of the enzyme-labelled Mabs to T. pallidum was performed. Inhibition of the seroreactivity of Mabs was decreased according to the dilution of rabbit antiserum to T. pallidum. Seropositivity was found in 100% of secondary and early latent syphilis patients, 75% of primary syphilis patients, and 80% of late latent syphilis patients. The mean percentage inhibition was significantly higher in each syphilis group than in the controls, and statistically significant differences were shown between all the syphilis groups. VDRL and TPHA titers were correlated with the percentage inhibitions. Therefore the ELISA inhibition test using Mab specific for T. pallidum might well be a suitable tool as a new serologic test for syphilis.
AuthorsK K Whang, M G Lee, M S Song, J B Lee
JournalActa dermato-venereologica (Acta Derm Venereol) Vol. 75 Issue 5 Pg. 397-9 (Sep 1995) ISSN: 0001-5555 [Print] Sweden
PMID8615063 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Bacterial
  • Antibodies, Monoclonal
  • Immune Sera
Topics
  • Analysis of Variance
  • Animals
  • Antibodies, Bacterial
  • Antibodies, Monoclonal
  • Binding, Competitive
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Hybridomas
  • Immune Sera
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Rabbits
  • Syphilis Serodiagnosis (methods)
  • Syphilis, Latent (diagnosis)
  • Treponema pallidum (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: